US · STOK
Stoke Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bedford, MA 01730
- Website
- stoketherapeutics.com
Price · as of 2024-12-31
$33.08
Market cap 2.08B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $49.24 | +48.85% |
| Intrinsic Value(DCF) | $1,957.13 | +5,816.35% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $25.35 | ||||
| 2020 | $51.26 | ||||
| 2021 | $20.44 | ||||
| 2022 | $8.74 | ||||
| 2023 | $7.57 | $21.24 | $0.73 | $0.00 | $47.12 |
| 2024 | $8.01 | $49.24 | $2.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Stoke Therapeutics, Inc.'s (STOK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $49.24
- Current price
- $33.08
- AI upside
- +48.85%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,957.13
+5,816.35% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| STOK | Stoke Therapeutics, Inc. | $33.08 | 2.08B | +49% | +5,816% | — | — | -4.86 | 1.89 | 11.83 | -2.20 | — | 1.89 | 100.00% | -277.31% | -243.42% | -45.80% | 800.63% | -35.60% | 0.01 | — | 5.81 | 5.43 | 1.27 | -3067.00% | 31634.00% | 529.00% | -20.12% | -2.17 | 687.55% | 0.00% | 0.00% | 0.00% | -2.15 | -2.50 | 5.96 | 3.33 |
| ARDX | Ardelyx, Inc. | $6.55 | 1.59B | +365% | +11,362% | — | — | -25.32 | 9.34 | 3.83 | -51.64 | -47.82 | 9.34 | 90.29% | -10.06% | -15.12% | -36.21% | -43.02% | -13.14% | 1.27 | -1.44 | 4.31 | 3.80 | -4.92 | 5294.00% | 2209.00% | -403.00% | -2.82% | -0.48 | -46.17% | 0.00% | 0.00% | 0.00% | -36.76 | -34.26 | 3.70 | 1.40 |
| BCRX | BioCryst Pharmaceuticals,… | $8.75 | 1.84B | +993% | +143,402% | -35% | +1,311% | 6.86 | -15.20 | 2.07 | 4.45 | — | -15.20 | 97.82% | 38.98% | 30.16% | -88.68% | -199.20% | 52.53% | -0.10 | 4.32 | 2.06 | 1.40 | -0.22 | -38140.00% | 9410.00% | -75364.00% | 19.18% | 1.77 | -205.64% | 0.00% | 0.00% | 44.97% | 4.54 | 4.46 | 1.77 | 1.99 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| NVAX | Novavax, Inc. | $10.14 | 1.65B | +505% | +13,192% | +19% | +1,774% | 3.72 | -12.82 | 1.46 | 2.34 | — | -6.79 | 93.50% | 50.14% | 39.19% | -117.16% | -58.11% | 32.17% | -1.95 | 24.98 | 2.13 | 1.83 | 0.02 | -30650.00% | 6469.00% | 14940.00% | -15.28% | -0.53 | 25.92% | 0.00% | 0.00% | 0.29% | 2.04 | -4.60 | 1.02 | -1.62 |
| PHVS | Pharvaris N.V. | $28.39 | 1.84B | — | — | — | — | -5.23 | 2.59 | — | -2.84 | — | 2.59 | 0.00% | — | — | -40.62% | 1529.52% | -38.37% | 0.00 | — | 12.60 | 12.35 | 1.92 | -570.00% | — | 2956.00% | -17.42% | -5.23 | 1266.85% | 0.00% | 0.00% | 0.00% | -2.83 | -3.42 | — | 15.12 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| WVE | Wave Life Sciences Ltd. | $13.93 | 2.59B | +134% | -54% | — | +334% | -11.43 | 4.51 | 54.67 | -8.57 | -15.69 | 4.51 | 0.00% | -504.09% | -478.33% | -56.16% | 323.63% | -108.74% | 0.03 | — | 6.47 | 6.35 | 2.86 | 7286.00% | -6055.00% | 2338.00% | -8.03% | -1.97 | 281.72% | 0.00% | 0.00% | 13.17% | -8.13 | -9.34 | 40.99 | 1.20 |
| ZBIO | Zenas BioPharma, Inc. | $26.35 | 1.1B | -12% | -81% | — | +1,012% | -1.98 | 1.00 | 62.26 | 0.23 | -0.69 | 1.00 | -2682.78% | -3277.76% | -3139.76% | -361.99% | 109.71% | -71.66% | 0.00 | — | 6.21 | 6.12 | 1.95 | 28763.00% | -9000.00% | 29221.00% | -38.49% | -2.09 | 80.20% | 0.00% | 0.00% | 90.91% | 0.23 | 0.32 | -7.69 | 1.30 |
| ZYME | Zymeworks Inc. | $23.29 | 1.74B | +9% | -79% | — | — | -7.42 | 2.69 | 11.93 | -6.47 | — | 2.83 | 100.00% | -179.69% | -160.80% | -30.54% | -110.26% | -23.51% | 0.05 | — | 3.40 | 3.19 | 0.44 | -581.00% | 38.00% | -757.00% | -12.43% | -1.25 | -90.96% | 0.00% | 0.00% | 3.30% | -5.13 | -6.21 | 9.21 | 1.62 |
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- CEO
- Ian F. Smith
- Employees
- 128
- Beta
- 1.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,957.13 ÷ $33.08) − 1 = +5,816.35% (DCF, example).